Research cost contribution under collaboration agreement treated as revenue expenditure when no enduring asset or advantage was acquired.

A contribution paid under a collaboration agreement towards a foreign collaborator's research and development costs was treated as revenue expenditure where the payment was linked to the assessee's manufacturing business and was not made for any technical information, licence, patent or research result. The payment was directed only to the collaborator's research establishment abroad and did not secure any capital asset or enduring business advantage for the assessee. On that basis, the amount could not be split into capital and revenue components merely because the research facility itself involved capital elements, and no disallowance as capital expenditure was warranted.

---

---

Issues: Whether any portion of the amount paid to the foreign collaborator as contribution towards research and development expenditure could be disallowed as capital expenditure.

Analysis: The payment under the collaboration agreement was specifically linked to the cost of research carried on by the foreign collaborator and was made for the assessee's manufacturing business. The agreement did not require any consideration for the supply of technical information, licences, patents, or research results, and the contribution under the relevant clause was directed only to the research establishment abroad. On the facts found, the payment had a direct business purpose and did not secure to the assessee any capital asset or enduring advantage. The statutory distinction between scientific research expenditure and general business expenditure did not justify treating the contribution as capital where the payment was for the assessee's own business use and was not for acquisition of a lasting asset.

Conclusion: No part of the contribution towards research and development expenditure was liable to be treated as capital expenditure, and the disallowance was rightly deleted.

Ratio Decidendi: A contribution made under a collaboration agreement towards the foreign collaborator's research costs, when made wholly for the assessee's business and without acquisition of any enduring asset or advantage, is revenue expenditure and cannot be split into a capital component merely because the research establishment may itself contain capital elements.

---